Mark A. Mintun

76.4k total citations · 23 hit papers
293 papers, 43.1k citations indexed

About

Mark A. Mintun is a scholar working on Physiology, Psychiatry and Mental health and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Mark A. Mintun has authored 293 papers receiving a total of 43.1k indexed citations (citations by other indexed papers that have themselves been cited), including 109 papers in Physiology, 101 papers in Psychiatry and Mental health and 100 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Mark A. Mintun's work include Alzheimer's disease research and treatments (90 papers), Dementia and Cognitive Impairment Research (90 papers) and Medical Imaging Techniques and Applications (69 papers). Mark A. Mintun is often cited by papers focused on Alzheimer's disease research and treatments (90 papers), Dementia and Cognitive Impairment Research (90 papers) and Medical Imaging Techniques and Applications (69 papers). Mark A. Mintun collaborates with scholars based in United States, United Kingdom and Belgium. Mark A. Mintun's co-authors include Marcus E. Raichle, Yvette I. Sheline, Peter T. Fox, John C. Morris, Abraham Z. Snyder, Jonathan D. Cohen, Steven E. Petersen, Michael I. Posner, Anne M. Fagan and David M. Holtzman and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Mark A. Mintun

284 papers receiving 41.9k citations

Hit Papers

Improved Assessment of Significant Activation in Function... 1984 2026 1998 2012 1995 1988 2005 1988 2006 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Improved Assessment of Significant Activation in Functional Magnetic Resonance Imaging (fMRI): Use of a Cluster‐Size Threshold
    1995 2.9k citations Jonathan D. Cohen, Mark A. Mintun et al. profile →
  2. Positron emission tomographic studies of the cortical anatomy of single-word processing
    1988 1.9k citations Mark A. Mintun et al. profile →
  3. Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory
    2005 1.6k citations Abraham Z. Snyder, Yvette I. Sheline et al. profile →
  4. Nonoxidative Glucose Consumption During Focal Physiologic Neural Activity
    1988 1.3k citations Mark A. Mintun et al. profile →
  5. BRAIN WORK AND BRAIN IMAGING
    2006 1.1k citations Mark A. Mintun et al. profile →
  6. The default mode network and self-referential processes in depression
    2009 1.1k citations Yvette I. Sheline, Deanna M. Barch et al. Proceedings of the National Academy of Sciences profile →
  7. Depression Duration But Not Age Predicts Hippocampal Volume Loss in Medically Healthy Women with Recurrent Major Depression
    1999 1.1k citations Yvette I. Sheline, Mark A. Mintun et al. profile →
  8. Positron Emission Tomographic Studies of the Processing of Singe Words
    1989 981 citations Mark A. Mintun et al. profile →
  9. Donanemab in Early Alzheimer’s Disease
    2021 969 citations Mark A. Mintun, Albert Lo et al. New England Journal of Medicine profile →
  10. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
    2005 960 citations Anne M. Fagan, Mark A. Mintun et al. profile →
  11. Spatial working memory in humans as revealed by PET
    1993 927 citations Robert A. Koeppe, Satoshi Minoshima et al. profile →
  12. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study
    2001 920 citations Yvette I. Sheline, Deanna M. Barch et al. Biological Psychiatry profile →
  13. Resting-state functional MRI in depression unmasks increased connectivity between networks via the dorsal nexus
    2010 908 citations Yvette I. Sheline, Joseph L. Price et al. Proceedings of the National Academy of Sciences profile →
  14. [ 11 C]PIB in a nondemented population
    2006 833 citations Mark A. Mintun, Yvette I. Sheline et al. Neurology profile →
  15. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography
    1984 794 citations Mark A. Mintun et al. profile →
  16. The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET
    2014 690 citations Robert A. Koeppe, Julie C. Price et al. Alzheimer s & Dementia profile →
  17. Cerebrospinal Fluid tau/β-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults
    2007 687 citations Anne M. Fagan, Catherine M. Roe et al. Archives of Neurology profile →
  18. APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
    2009 654 citations John C. Morris, Catherine M. Roe et al. profile →
  19. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study
    2012 572 citations Christopher M. Clark, Michael J. Pontecorvo et al. profile →
  20. Amyloid deposition, hypometabolism, and longitudinal cognitive decline
    2012 515 citations Mark A. Mintun, Abhinay D. Joshi et al. profile →
  21. Regional aerobic glycolysis in the human brain
    2010 513 citations Andrei G. Vlassenko, Melissa M. Rundle et al. Proceedings of the National Academy of Sciences profile →
  22. Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease
    2022 138 citations Michael J. Pontecorvo, Ming Lu et al. profile →
  23. Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease
    2025 29 citations Jennifer A. Zimmer, Paul Ardayfio et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark A. Mintun United States 96 20.2k 12.4k 12.3k 9.4k 4.6k 293 43.1k
Marilyn Albert United States 72 17.5k 0.9× 13.1k 1.1× 8.3k 0.7× 9.5k 1.0× 3.1k 0.7× 221 37.0k
Reisa A. Sperling United States 104 15.9k 0.8× 19.6k 1.6× 18.6k 1.5× 5.7k 0.6× 3.3k 0.7× 534 41.5k
Eric M. Reiman United States 102 10.5k 0.5× 11.9k 1.0× 15.1k 1.2× 4.5k 0.5× 2.9k 0.6× 469 34.5k
Robert A. Koeppe United States 94 13.1k 0.7× 7.9k 0.6× 8.4k 0.7× 4.7k 0.5× 6.2k 1.3× 385 34.4k
Bruno Dubois France 83 12.7k 0.6× 18.9k 1.5× 15.0k 1.2× 3.4k 0.4× 2.7k 0.6× 419 39.4k
Sandra Weıntraub United States 78 17.2k 0.8× 18.5k 1.5× 11.7k 1.0× 3.2k 0.3× 1.7k 0.4× 305 39.2k
Yaakov Stern United States 132 17.3k 0.9× 30.6k 2.5× 18.1k 1.5× 3.9k 0.4× 4.2k 0.9× 795 67.4k
Carlo Caltagirone Italy 94 15.8k 0.8× 8.9k 0.7× 4.5k 0.4× 4.4k 0.5× 3.8k 0.8× 900 36.8k
William J. Jagust United States 114 20.3k 1.0× 32.4k 2.6× 27.9k 2.3× 10.5k 1.1× 4.5k 1.0× 481 61.5k
William W. Seeley United States 81 13.1k 0.6× 7.1k 0.6× 8.3k 0.7× 3.9k 0.4× 2.8k 0.6× 274 27.0k

Countries citing papers authored by Mark A. Mintun

Since Specialization
Citations

This map shows the geographic impact of Mark A. Mintun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Mintun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Mintun more than expected).

Fields of papers citing papers by Mark A. Mintun

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Mintun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Mintun. The network helps show where Mark A. Mintun may publish in the future.

Co-authorship network of co-authors of Mark A. Mintun

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Mintun. A scholar is included among the top collaborators of Mark A. Mintun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Mintun. Mark A. Mintun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lu, Ming‐Chi, Amanda Sheffield Morris, Rose Beck, et al.. (2025). Analytical Validation and Performance of a Blood-Based P-tau217 Diagnostic Test for Alzheimer Disease. The Journal of Applied Laboratory Medicine. 10(3). 533–545. 4 indexed citations
2.
Martin, Corby K., Owen Carmichael, Susan Carnell, et al.. (2025). Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nature Medicine. 31(9). 3141–3150. 6 indexed citations
3.
Zimmer, Jennifer A., John R. Sims, Cynthia Evans, et al.. (2025). Donanemab in early symptomatic Alzheimer’s disease: results from the TRAILBLAZER-ALZ 2 long-term extension. The Journal of Prevention of Alzheimer s Disease. 13(2). 100446–100446.
4.
Wang, Hong, Emel Serap Monkul Nery, Paul Ardayfio, et al.. (2025). The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6. The Journal of Prevention of Alzheimer s Disease. 12(8). 100266–100266. 2 indexed citations
5.
Fleisher, Adam, Leanne Munsie, David Pérahia, et al.. (2024). Assessment of Efficacy and Safety of Zagotenemab. Neurology. 102(5). e208061–e208061. 17 indexed citations
6.
Hodsdon, Michael E., Ming‐Chi Lu, Amanda Sheffield Morris, et al.. (2024). Clinical validation of the Eli Lilly SPX P‐tau217 blood‐based immunoassay as a laboratory‐developed test (LDT). Alzheimer s & Dementia. 20(S8).
7.
Mintun, Mark A., Craig Ritchie, Paul R. Solomon, et al.. (2023). Donanemab in Early Symptomatic Alzheimer’s Disease: Efficacy and Safety in TRAILBLAZER‐ALZ 2, a Phase 3 Randomized Clinical Trial. Alzheimer s & Dementia. 19(S24). 6 indexed citations
8.
Evans, Cynthia, JonDavid Sparks, Scott W. Andersen, et al.. (2023). APOE ε4's impact on response to amyloid therapies in early symptomatic Alzheimer's disease: Analyses from multiple clinical trials. Alzheimer s & Dementia. 19(12). 5407–5417. 8 indexed citations
9.
Mintun, Mark A., Albert Lo, Cynthia Evans, et al.. (2021). Donanemab in Early Alzheimer’s Disease. New England Journal of Medicine. 384(18). 1691–1704. 969 indexed citations breakdown →
10.
Johnson, Keith A., Reisa A. Sperling, Christopher Gidicsin, et al.. (2013). Florbetapir (F18‐AV‐45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimer s & Dementia. 9(5S). S72–83. 190 indexed citations
11.
Roe, Catherine M., Anne M. Fagan, Monique Williams, et al.. (2011). Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease. Neurology. 76(6). 501–510. 35 indexed citations
12.
Fagan, Anne M., Leslie M. Shaw, Chengjie Xiong, et al.. (2011). Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of β-Amyloid 1-42, Total tau, and P-tau181 for Identifying Alzheimer Disease Amyloid Plaque Pathology. Archives of Neurology. 68(9). 1137–1137. 137 indexed citations
13.
Galvin, James E., Anne M. Fagan, David M. Holtzman, Mark A. Mintun, & John C. Morris. (2010). Relationship of dementia screening tests with biomarkers of Alzheimer's disease. Brain. 133(11). 3290–3300. 75 indexed citations
14.
Sheline, Yvette I., et al.. (2010). Resting-state functional MRI in depression unmasks increased connectivity between networks via the dorsal nexus. Proceedings of the National Academy of Sciences. 107(24). 11020–11025. 908 indexed citations breakdown →
15.
Fales, Christina L., Deanna M. Barch, Melissa M. Rundle, et al.. (2007). Altered Emotional Interference Processing in Affective and Cognitive-Control Brain Circuitry in Major Depression. Biological Psychiatry. 63(4). 377–384. 408 indexed citations
16.
Chen, Delphine L., Mark A. Mintun, & Daniel P. Schuster. (2004). Comparison of methods to quantitate 18F-FDG uptake with PET during experimental acute lung injury.. PubMed. 45(9). 1583–90. 46 indexed citations
17.
Mintun, Mark A., Yvette I. Sheline, Stephen M. Moerlein, et al.. (2003). Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography. Biological Psychiatry. 55(3). 217–224. 121 indexed citations
18.
Sheline, Yvette I., et al.. (2002). The hippocampus and depression. European Psychiatry. 17(S3). 300s–305s. 134 indexed citations
19.
Nofzinger, Eric A., Mark A. Mintun, Julie C. Price, et al.. (1998). A method for the assessment of the functional neuroanatomy of human sleep using FDG PET. Brain Research Protocols. 2(3). 191–198. 35 indexed citations
20.
Minoshima, Satoshi, Robert A. Koeppe, Jeffrey A. Fessler, et al.. (1993). Integrated and automated data analysis method for neuronal activation studies using O-15 water PET. Annals of Nuclear Medicine. 7. 409–415. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marilyn Albert Breakdown of academic impact, for papers by Reisa A. Sperling Breakdown of academic impact, for papers by Eric M. Reiman Breakdown of academic impact, for papers by Robert A. Koeppe Breakdown of academic impact, for papers by Bruno Dubois Breakdown of academic impact, for papers by Sandra Weıntraub Breakdown of academic impact, for papers by Yaakov Stern Breakdown of academic impact, for papers by Carlo Caltagirone Breakdown of academic impact, for papers by William J. Jagust Breakdown of academic impact, for papers by William W. Seeley
Rankless by CCL
2026